Nifty99000 100%

Sensex99000 100%

Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
Article rating: No rating
RSS

News

Indian healthcare may grow threefold to $372 bn by 2022: Assocham

Author: IANS/Monday, December 4, 2017/Categories: Healthcare

Indian healthcare may grow threefold to $372 bn by 2022: Assocham

New Delhi, Dec 3 - The Indian healthcare market is likely to reach $372 billion by 2022 in a threefold growth in value terms, industry chamber Assocham said on December 3, citing its latest study on the subject.

"India's healthcare market may see threefold rise as its size in value terms is likely to reach $372 billion by 2022 from the level of $110 bn as of 2016, thereby clocking a compounded annual growth rate (CAGR) of 22%," an Assocham release said here, citing the Assocham-RNCOS joint paper. 

"Growing lifestyle diseases, rising demand for affordable healthcare due to increasing healthcare costs, technological advancements, emergence of telemedicine, rapid health insurance penetration, mergers and acquisitions helping to reach untapped markets and government initiatives like tax benefits, incentives and a host of regulatory policies are driving the healthcare market in India," the study said.

The paper "Indian Healthcare Sector- An Overview" said that factors like growing geriatric population, uptick in medical tourism and gradual decline in cost of medical services will drive the domestic medical devices market, which was valued at $4 billion in 2016 and is likely to cross the $11 billion mark by 2022, registering a CAGR of 15 per cent.

Imports, however, make up about 75% of Indian medical devices market, according to the study. 

It said generic drugs account for about 70% of the $20 billion worth Indian pharmaceutical market.

"Increasing expenditure on research and development (R&D), rising collaborations between Indian and foreign companies, reduction in product approval time and other such factors are driving the growth of Indian pharmaceutical market," the study said.

It also noted that the Goods and Services Tax (GST) will have a positive impact on the Indian healthcare market, particularly on the pharmaceutical sector.

"GST would not only streamline taxation structure but lead to ease of doing business by minimising cascading effect of many taxes applied to a product, rationalise supply chain, enable flow of seamless tax credit, lower manufacturing cost, reduce cost of technology and make healthcare affordable," it said.

According to Assocham, the Indian pharmaceutical market is third largest globally in terms of volume and 13th largest in terms of value.

Print Rate this article:
No rating

Number of views (121)/Comments (0)

Kavita Giridhar Mallya

IANS

Other posts by IANS
Contact author

Leave a comment

Name:
Email:
Comment:
Add comment

Name:
Email:
Subject:
Message:
x

Videos

Ask the Finapolis.

I'm not a robot
 
Dharmendra Satpathy
Col. Sanjeev Govila (retd)
Hum Fauji Investments
 
The Finapolis' expert answers your queries on investments, taxation and personal finance. Want advice? Submit your Question above
Want to Invest
 
 

Categories

Disclaimer

The technical studies / analysis discussed here can be at odds with our fundamental views / analysis. The information and views presented in this report are prepared by Karvy Consultants Limited. The information contained herein is based on our analysis and upon sources that we consider reliable. We, however, do not vouch for the accuracy or the completeness thereof. This material is for personal information and we are not responsible for any loss incurred based upon it. The investments discussed or recommended in this report may not be suitable for all investors. Investors must make their own investment decisions based on their specific investment objectives and financial position and using such independent advice, as they believe necessary. While acting upon any information or analysis mentioned in this report, investors may please note that neither Karvy nor Karvy Consultants nor any person connected with any associate companies of Karvy accepts any liability arising from the use of this information and views mentioned in this document. The author, directors and other employees of Karvy and its affiliates may hold long or short positions in the above mentioned companies from time to time. Every employee of Karvy and its associate companies is required to disclose his/her individual stock holdings and details of trades, if any, that they undertake. The team rendering corporate analysis and investment recommendations are restricted in purchasing/selling of shares or other securities till such a time this recommendation has either been displayed or has been forwarded to clients of Karvy. All employees are further restricted to place orders only through Karvy Consultants Ltd. This report is intended for a restricted audience and we are not soliciting any action based on it. Neither the information nor any opinion expressed herein constitutes an offer or an invitation to make an offer, to buy or sell any securities, or any options, futures or other derivatives related to such securities.